Insider Selling: IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Sells 9,986 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

IDEXX Laboratories Stock Performance

IDXX traded down $1.17 on Tuesday, hitting $463.74. The company had a trading volume of 493,929 shares, compared to its average volume of 726,423. The company’s fifty day moving average price is $429.03 and its 200 day moving average price is $453.28. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The stock has a market cap of $37.98 billion, a price-to-earnings ratio of 43.46, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37.

Institutional Investors Weigh In On IDEXX Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the last quarter. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $30,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $31,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on IDXX shares. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday. Finally, Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.